Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France

Launched by CENTRE DE RECHERCHES ET D'ETUDE SUR LA PATHOLOGIE TROPICALE ET LE SIDA · Jan 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the real-world use of a medication called Lenacapavir (LEN) for people living with HIV-1 who have had trouble with other treatments. LEN, which is a new type of drug that helps fight HIV, was found to be effective in a previous trial, where many patients achieved low levels of the virus in their blood. The goal of this new study is to gather information about how well LEN works in everyday settings in France, particularly looking at different patient profiles and whether patients continue their treatment over time.

To be eligible for this study, participants must be adults aged 18 and older with HIV-1 infection who have started treatment with LEN and an optimized background regimen since June 20, 2023. Participants will have their health information collected to help researchers understand how LEN is being used and the reasons why some patients may stop treatment. This study is important because it will provide valuable insights into the effectiveness of LEN in treating HIV in a real-world context, contributing to better care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (≥18 years);
• • With HIV-1 infection;
• • Who received a first dose of LEN (oral or injectable) with and OBR from the ending of the French national early access program (20 June 2023) to 30 June 2024;
• • Who did not refuse the collection and use of their data.
• Exclusion Criteria:
• • - HIV-2 infection.